Changes in Signal Transduction Pathways — AP Biology
AP Biology · AP Biology CED Unit 4 · 14 min read
Covers: This subtopic covers permanent (mutation) and transient (chemical) changes to signal transduction pathways, their effects on cellular response, phenotypic consequences, and links to disease and drug action, tested frequently on both AP Bio MCQ and FRQ.
You should already know:
Basic signal transduction pathway structure
G protein-coupled receptors and phosphorylation cascades
Core cell cycle checkpoint function
Distinguish between gain-of-function and loss-of-function mutations in signal transduction
Classify signaling molecules as agonists or antagonists of pathway activity
Predict phenotypic outcomes of altered second messenger signaling
Trace causal links from molecular change to cellular and organismal phenotype
1. Mutations Altering Signal Transduction Pathways ★★☆☆☆ ⏱ 4 min Most heritable changes to signal transduction arise from point mutations, insertions, or deletions in genes encoding signaling proteins, including receptors, downstream kinases, phosphatases, or transcription factors. A mutation that changes the amino acid sequence of a signaling protein produces one of two broad functional outcomes.
Mutation Functional Classes
**Loss-of-function (LOF)**: Eliminates or reduces protein activity, resulting in a pathway that cannot activate when it should be turned on. **Gain-of-function (GOF)**: Increases or unregulates protein activity, resulting in a pathway that is active even when it should be turned off. The most common GOF outcome for growth pathways is constitutive activation.
Example: Constitutive activation of growth factor receptors causes unregulated cell division
The gene encoding the epidermal growth factor receptor (EGFR), a transmembrane receptor that triggers cell division when bound to EGF ligand, has a missense mutation that replaces a cysteine in the extracellular ligand-binding domain with arginine. This change alters folding of the binding domain and prevents formation of the disulfide bond required for ligand binding. Predict the effect of this mutation on signal transduction and cell behavior.
First, classify the mutation's effect on receptor function: the mutation eliminates the ability to bind ligand, so this is a loss-of-function mutation.
Without ligand binding, the receptor cannot dimerize or undergo the conformational change required to activate the downstream phosphorylation cascade that triggers cell division.
In cells that require EGF signaling to enter the cell cycle, this mutation will result in a failure to divide even when EGF is present at normal concentrations in the extracellular environment.
Unlike a gain-of-function EGFR mutation that causes unregulated division, this mutation in a single somatic cell produces a non-dividing cell and is not cancer-causing.
Exam tip: Always trace the effect of a mutation step-by-step from the altered protein through the entire pathway to the final phenotype; AP FRQ graders require this explicit chain of reasoning, not just a final outcome.
2. Chemical Disruption of Signal Transduction ★★☆☆☆ ⏱ 4 min Unlike permanent mutations, chemical disruptions are transient changes to pathway function caused by exogenous molecules (drugs, toxins, pollutants) that interact with signaling proteins. Chemicals are categorized by their effect on pathway activity, and this mechanism is the basis for most modern pharmaceutical development targeting disease.
Agonists vs Antagonists
**Agonists**: Activate the pathway, usually by mimicking the natural ligand and triggering receptor activation. **Antagonists**: Inhibit pathway activation by blocking receptor or downstream protein function. Antagonists act via competitive inhibition (bind the ligand-binding site) or non-competitive inhibition (bind an allosteric site to alter receptor conformation).
Tamoxifen is used to treat estrogen receptor-positive (ER+) breast cancer. Estrogen binding to the intracellular estrogen receptor triggers a conformational change that allows ER to translocate to the nucleus and bind promoter regions of genes that promote cell division. Tamoxifen binds to the ligand-binding domain of ER, blocks estrogen binding, and does not trigger the conformational change needed for ER to bind DNA. Is tamoxifen an agonist or antagonist, and what effect does it have on ER+ cancer cell division?
First, recall core definitions: agonists activate pathway signaling, antagonists block pathway activation.
Tamoxifen binds the ligand-binding site, prevents the natural ligand (estrogen) from binding, and does not induce the active conformation of ER.
Without an active conformation, ER cannot translocate to the nucleus or activate transcription of cell division genes.
Transcription of growth-promoting genes is blocked, so ER+ cancer cell division is inhibited. Tamoxifen is therefore an antagonist that slows tumor growth.
Exam tip: Do not confuse competitive and non-competitive inhibition of receptors; competitive inhibitors bind the ligand-binding site, so their effect can be overcome by high natural ligand concentration, while non-competitive inhibitors cannot be overcome this way.
3. Altered Second Messenger Signaling ★★★☆☆ ⏱ 3 min Many signal transduction pathways use small, diffusible second messengers (e.g., cAMP, Ca²⁺, IP₃) to amplify the original signal downstream of receptor activation. Changes in the concentration or availability of second messengers can drastically alter pathway output even if the receptor and upstream components are unmutated.
Because second messengers amplify the original signal, even a small change in their concentration leads to a very large change in cellular response. This is why low doses of toxins targeting second messengers often cause severe physiological effects.
Cholera toxin enters intestinal epithelial cells and modifies the Gα subunit of G proteins, preventing Gα from hydrolyzing GTP to GDP. Gα is only active when bound to GTP. Active Gα constantly activates adenylyl cyclase, which produces cAMP from ATP. Predict the effect of this toxin on cAMP levels and the resulting physiological outcome.
Because Gα cannot hydrolyze GTP to GDP, it remains permanently active, so adenylyl cyclase continuously produces cAMP. This results in constitutively high cAMP levels in the cell.
High cAMP activates protein kinase A, which phosphorylates and opens chloride channels in the intestinal epithelial cell membrane.
Chloride ions flow out of the cell into the intestinal lumen, followed by sodium and water moving down their concentration gradients out of the cell.
The excess water and salt in the lumen causes the watery diarrhea characteristic of cholera infection. This effect is transient, caused by toxin activity rather than a permanent mutation, so it resolves once the toxin is cleared.
Exam tip: Do not forget that second messengers serve a core purpose of signal amplification; always mention amplification when explaining why a small change in upstream signaling produces a large physiological response.
4. AP Style Practice Problems ★★★☆☆ ⏱ 3 min
A point mutation in the gene encoding RAS, a downstream component of the growth factor signaling pathway that promotes cell division, prevents RAS from hydrolyzing GTP to GDP. RAS is only active when bound to GTP. Which of the following best describes the effect of this mutation?<br>A) Loss-of-function mutation that causes decreased cell division<br>B) Gain-of-function mutation that causes constitutive activation of cell division signaling<br>C) Loss-of-function mutation that prevents growth factor from binding its receptor<br>D) Gain-of-function mutation that blocks the phosphorylation cascade leading to cell division
First, map the normal function of RAS: RAS is active when GTP-bound, inactive when GDP-bound. The mutation prevents GTP hydrolysis, so RAS remains permanently GTP-bound and active.
This is a gain-of-function mutation because RAS has gained unregulated activity, eliminating options A and C.
Option D is incorrect because active RAS triggers, not blocks, the downstream phosphorylation cascade that leads to cell division. Only option B correctly describes the mutation.
The insulin signaling pathway regulates blood glucose levels: 1) Insulin binds to its receptor tyrosine kinase on the cell surface; 2) the receptor autophosphorylates and activates downstream signaling; 3) downstream signaling triggers translocation of glucose transporters (GLUT4) to the cell membrane; 4) glucose enters the cell from the bloodstream, lowering blood glucose levels.<br>(a) In type 2 diabetes, cells become resistant to insulin, meaning insulin binds the receptor but the downstream pathway does not activate. Predict one possible change to a signaling component that could cause this insulin resistance. Justify your prediction.<br>(b) Sulfonylureas are a class of drugs that bind to and close ATP-sensitive K⁺ channels on pancreatic beta cells. Open K⁺ channels maintain the resting membrane potential of beta cells; closing the channels causes depolarization that triggers insulin release. Are sulfonylureas agonists or antagonists of the K⁺ channel? Justify your answer.<br>(c) Explain how a heritable change in the insulin signaling pathway that increases fasting glucose tolerance could be selected for in human populations with historically low food availability.
(a) One possible change is a loss-of-function mutation in the intracellular domain of the insulin receptor. Justification: Insulin binds correctly to the extracellular domain, but the intracellular domain cannot be phosphorylated to activate downstream signaling. This means GLUT4 translocation is not triggered even when insulin is bound, leading to insulin resistance.
(b) Sulfonylureas are antagonists of the K⁺ channel. Antagonists inhibit the normal function of a target protein; the normal function of open ATP-sensitive K⁺ channels is to allow K⁺ flow to maintain resting membrane potential. Closing the channel inhibits its normal function, so sulfonylureas act as antagonists.
(c) In populations with low food availability, individuals with heritable changes that maintain higher blood glucose levels during fasting (by reducing insulin signaling efficiency) have more stable glucose available for brain and muscle function during long periods without food. These individuals are more likely to survive periods of famine and reproduce, passing the altered pathway allele to their offspring. Over generations, the allele increases in frequency via natural selection.
A research team is testing a new inhaled drug for asthma that targets the beta-2 adrenergic receptor (B2AR) on smooth muscle cells surrounding airway passages. Activation of B2AR triggers a cAMP-dependent pathway that causes smooth muscle relaxation, opening constricted airway passages. Albuterol, a common asthma medication, is a B2AR agonist with a binding dissociation constant of $K_d = 1.5 \times 10^{-8}$ M. The new drug has a binding dissociation constant of $K_d = 3.2 \times 10^{-10}$ M.<br>(a) Which drug binds B2AR more tightly? Justify your answer.<br>(b) Predict how the new drug will affect airway diameter in an asthma patient experiencing a bronchoconstriction (narrowed airways) attack. Explain your reasoning in terms of signal transduction.
(a) The dissociation constant $K_d$ is inversely related to binding affinity: a lower $K_d$ means less ligand dissociates from the receptor at equilibrium, indicating tighter binding. The new drug has a lower $K_d$ ($3.2 \times 10^{-10}$ M < $1.5 \times 10^{-8}$ M), so it binds B2AR more tightly than albuterol.
(b) As a high-affinity agonist for B2AR, the new drug will bind B2AR and trigger conformational activation of the receptor. Activated B2AR activates Gα, which in turn activates adenylyl cyclase to produce cAMP. High cAMP levels trigger the protein kinase A cascade that leads to smooth muscle relaxation. Relaxation of airway smooth muscle increases airway diameter, reversing bronchoconstriction and relieving asthma symptoms.
Common Pitfalls
Why: Students confuse gain/loss of normal regulation with gain/loss of total protein activity
Why: Students mix up the direction of pathway effect and chemical action
Why: Students associate changes with mutations, forgetting chemical exposure causes transient, non-heritable changes
Why: Students focus on mechanism and forget to answer the question’s prompt for the organism or cellular level outcome
Why: Students memorize by first letter rather than functional definition
Quick Reference Cheatsheet